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Objective: To determine the 12-month cost-effectiveness of a collaborative care (CC) program for treating
depression following coronary artery bypass graft (CABG) surgery versus physicians' usual care (UC).
Methods: We obtained 12 continuous months of Medicare and private medical insurance claims data on 189
patients who screened positive for depression following CABG surgery, met criteria for depression when
reassessed by telephone 2weeks following hospitalization (nine-item Patient Health Questionnaire≥10) and
were randomized to either an 8-month centralized, nurse-provided and telephone-delivered CC intervention
for depression or to their physicians' UC.
Results: At 12 months following randomization, CC patients had $2068 lower but statistically similar estimated
median costs compared to UC (P=.30) and a variety of sensitivity analyses produced no signiﬁcant changes. The
incremental cost-effectiveness ratio of CC was−$9889 (−$11,940 to−$7838) per additional quality-adjusted
life-year (QALY), and there was 90% probability it would be cost-effective at the willingness to pay threshold of
$20,000 per additional QALY. A bootstrapped cost-effectiveness plane also demonstrated a 68% probability of CC
“dominating” UC (more QALYs at lower cost).
Conclusions: Centralized, nurse-provided and telephone-delivered CC for post-CABG depression is a quality-
improving and cost-effective treatment that meets generally accepted criteria for high-value care.
© 2014 Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/3.0/).Approximately one in four patients with cardiac disease report
signiﬁcant elevations in mood symptoms, and strong evidence links
depression to reduced health-related quality of life (HRQoL) [1–3],
increased morbidity and mortality [4–8], and higher treatment costs
independent of cardiac disease severity [9]. Randomized trials clearly
demonstrate that effective depression treatment can reduce
mood symptoms and improve HRQoL in patients with cardiac disease
[2,10–13], and despite conﬂicting opinions [2,10,14,15], an AmericanIdentiﬁer: NCT00091962
ollman+cabg&rank=1).
f Health Grants R01 HL70000
C.F. Reynolds), and by a grant
ittsburgh, PA 15213, USA. Tel.:
).
article under the CC BY-NC-ND liceHeart Association (AHA) Science Advisory recommends that screen-
ing and treatment programs for depression be deployed into routine
cardiac care [16].
Numerous trials have supported the effectiveness [17] and cost-
effectiveness [18–21] of collaborative care (CC) strategies for treating
depression in primary care settings. Based on Wagner's Chronic Care
Model [22], it involves care managers who follow an evidence-based
treatment protocol under the supervision of a primary care physician
(PCP) and systematically contact patients to monitor their mood
symptoms and recommend adjustments in treatment accordingly.
Yet, CC has not been widely adopted in primary care let alone cardiac
care settings. Given the concern about rising health care costs and
resource limitations, payers and health systems are likely to require
rigorous economic analyses before investing in new programs. Still,
just one group has reported the cost-effectiveness of a depression
treatment program for patients with cardiac disease [23,24].nse (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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apply a CC approach for treating depression following an acute cardiac
event [25], and reported that an 8-month nurse-led and telephone-
delivered CC intervention for treating depression following coronary
artery bypass graft (CABG) surgery could produce higher levels of
HRQoL and lower levels of mood symptoms [12] and pain [26] than
patients randomized to their doctors' usual care (UC). We now report
the 12-month cost-effectiveness of the BtB intervention strategy.
1. Methods
BtB compared the impact of telephone-delivered CC for treating
post-CABGdepressionversus doctors' UConHRQoL (primaryoutcome),
mood symptoms, physical functioning, health services utilization
and health care costs. All study procedures were approved by the
institutional review boards of the (University of Pittsburgh) and our
study hospitals, and by an independent data and safety monitoring
board appointed by the National Heart Lung and Blood Institute.
Published details of the BtB protocol [25], recruitment patterns and
main clinical outcomes [12,25] are brieﬂy summarized herein.
1.1. Setting and participants
From 3/2004 to 9/2007when our randomization targetwas achieved
(TargetN=300) [12], studynurse-recruiters identiﬁed2485hospitalized
patients who had just undergone CABG surgery at one of seven
Pittsburgh-area hospitals and provided their signed informed consent
to undergo our depression screening procedure with the Patient Health
Questionnaire (PHQ-2) [27]. Of these, 1387 (56%) screened positive and
1268 (91%)met all preliminary eligibility criteria and consented to enroll
into our trial and allow us to obtain claims data from their insurer should
they remain protocol-eligible following our 2-week telephone follow-up
assessment. Later, 1100 (87%) completed the PHQ-9 [28] following
hospital discharge and 337 (31%) scored ≥10 signifying at least a
moderate level of depressive symptoms.Of these, 302 (90%)met all other
eligibility criteria andwere randomized to either their physicians' “usual
care” (UC) (n=152) or our CC intervention (n=150).
1.2. CC intervention
Following randomization, a nurse care manager telephoned
intervention patients to review their psychiatric history, provide
basic psychoeducation about depression and describe various treat-
ment options that included the following: (1) a workbook we mailed
patients to enhance their ability to self-care for depression [29];
(2) initiation or adjustment of a course of antidepressant pharmaco-
therapy prescribed under their PCPs' direction; (3) assistance with
referral to a local mental health specialist in the event of poor treatment
response, severe psychopathology or complex psychosocial problems;
or (4) “watchful waiting” for mildly elevated mood symptoms.
The care manager subsequently presented the patient's information
to the study psychiatrist and internist at a weekly case-review session.
Treatment recommendationswere then formulated and conveyedby the
nurse to the patient via telephone, and to his/her PCP for consideration
via fax, telephone or mail depending upon the urgency of response.
However, we required that PCPs approve and prescribe all of their
patients' pharmacotherapy and we never dispensed any medications.
During the “acute phase” of treatment, the caremanager telephoned
patients biweekly to administer the PHQ-9 and assess treatment
response, monitor antidepressant pharmacotherapy, review workbook
lesson plans and inform them of new treatment recommendations
generated at our case-review sessions. Depending upon a patient's
treatment choice(s), symptoms and motivation, these telephone
contacts lasted 15–45min and continued for 2 to 4months. The patient
subsequently transitioned to the “continuation phase” of care duringwhich the care manager initiated contacts every 1–2 months until
completion of our 8-month intervention.
1.3. Patient-level outcomes
Nurse-recruiters collected information on patients' sociodemographic
characteristics andconductedadetailedchart reviewof comorbidmedical
conditions, and medication use prior to hospital discharge. Telephone
assessors blinded to the patient's treatment assignment administered the
short-form (36) (SF-36) [30] to determine generic mental component
summary (MCS) andphysical component summary (PCS)HRQoL, and the
17-item Hamilton Rating Scale for Depression (HRS-D) [31] at baseline
and at 2, 4, 8 and 12 months following randomization. We attempted to
complete 8-month telephone assessments on all patients (8 months was
our trial's “main outcomes” time point [12]) and 12-month telephone
assessments on all who were enrolled for at least 12 months at the time
we concluded our ﬁnal 8-month telephone assessment.
We used the approach developed by Lave et al. [32] to calculate the
effectiveness of our intervention in terms of added quality-adjusted life-
years (QALYs) and depression-free days (DFDs). To estimate QALYs, we
converted theSF-36 scores collectedat each timepoint into apreference-
based utility between 0 (death) and 1 (perfect health) summed over a
12-month period [33]. Similarly, to calculate DFDs, we categorized the
HRS-D score at each timepoint as either a “full”DFD (HRS-D≤7), partial
DFD (HRS-D N7≤21weighted proportionately), or a “zero”DFD (HRS-D
N21) that we summed over the total 12-month period.
1.4. Cost analyses
We conducted our cost analyses from the perspective of the health
care payer. In an a priori economic power calculation submitted to our
funding agency (2002), we estimated that 150 subjects per trial arm
would provide 90% power to detect log-transformed differences of
$2400 between-groups assuming an intent-to-treat analytic plan,
two-tailed alpha ≤ .05, ≤5% missing claims rate and 12-month UC
medical costs of $3400 following CABG surgery.
We sought all available medical claims and enrollment data from
Medicare and the two largest private insurers in western Pennsylvania
who covered the majority of BtB participants to 12/31/2008 so as to
ensure that the last randomized patients had 12 months of follow-up
claims.We included trial patients whowere continuously enrolledwith
these three insurers for a 12-month period following the date of
randomization including thosewho switched fromone of these plans to
another and those with Medicare plus a supplemental Medigap policy
through one of the two private insurers. Using outpatient and inpatient
insurance claims data, we then constructedmeasures of total 12-month
health care spending. Outpatient costs included physician visits to PCPs
and specialists, laboratory testing, imaging, emergency department use,
facility fees and all other outpatient health care. Inpatient costs included
all acute inpatient medical or surgical admissions but excluded the
initial admission for CABG surgery or any other care prior to
randomization. Although self-reported rates of antidepressant pharma-
cotherapy use differed slightly at 8-month follow-up (44% CC vs. 31%
UC; P=.008 [12]), we did not include prescription drug spending
because Medicare lacked a drug beneﬁt until 2006, and increasing
numbers of patients over the course of the trial were utilizing
pharmacies that offered a month's supply of a generic antidepressant
for $4 without generating an insurance claim [34].
To account for differences in reimbursement rates across our three
payers, we assigned standard Medicare costs to the claims-based
utilization data. We obtained the mean cost per discharge by
diagnosis-related group from the 2007 Healthcare Costs and Utiliza-
tion Project National Inpatient Sample and merged it with the
inpatient data (http://www.hcup-us.ahrq.gov). We determined the
mean cost per physician visit/procedure using the Medicare Part B
Extract Summary System by CPT code and assigned a cost to all
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Because of limited power, skewed cost data, and to avoid making
multiple comparisons with small sample sizes, we restricted our
analyses to those of total outpatient, inpatient and overall total costs.
We estimated the mean 8-month cost of our intervention at $460 per
patient. We calculated this value using the following: (1) the median
number of 10 telephone contactsmade by our nurse caremanagers to each
patient over the course of his or her participation in our 8-month
intervention (range: 0–28) [12], (2) trial documentation that each call
took approximately 1 h of time (25 min call+35 min recordkeeping and
other outreach efforts) and (3) the actual salary and fringe beneﬁt rate paid
toourstudynurses ($31/h×10=$310). Then,perKatonetal. [20],weadded
aﬁxed $100 for each patient to cover the costs of physician supervision and
our caremanager's tracking registry [20,25], plus an additional $50 to cover
the cost of our workbook, mailings and other miscellaneous support.
1.5. Statistical analyses
We compared baseline sociodemographic, clinical and functional
status measures by both availability of complete 12-month claims data
and randomization status using t-tests for continuous data and chi-square3790 Post-CABG patients signed
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Fig. 1. CONSORT ﬂowchart. HIPAA indicates Health Insurance Portability and Accountabanalyses for categorical data. We calculated the incremental cost-
effectiveness ratio (ICER) of our intervention using both actual and
estimatedmeasures of effectiveness and costs. To estimateQALYs,weﬁrst
estimated the preference-based utilities at each time point using amixed
model that included treatment, time point, age, gender and race as
independent variables and each subject as a random intercept to account
for unobserved heterogeneity among individuals. We then added two-
and three-way interaction terms between treatment, time point and
gender to the model to account for observed gender differences in
treatment response [12], with time treated as a categorical variable. We
used the iterative Markov chain Monte Carlo method to impute missing
valuesof our effectivenessmeasure, and calculated themeanutilities from
the two adjacent time points and summed the product of themean utility
and the duration of time between those points.
To estimate total 12-month costs, we used generalized linear
models (GLMs) with Gamma distribution to correct for skewness in
our cost data given the large differences between the actual mean
and median costs. The model included a log-link function with
treatment group, age, gender and race as independent variables, and
an interaction term of treatment×gender. We then calculated the
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ility Act; MDD, major depressive disorder; MMSE, Mini-Mental State Examination.
Table 1
Baseline sociodemographic, clinical and mental health characteristics among depressed post-CABG patients by inclusion in our cost-effectiveness analyses (CEA) and
randomization status
Included in cost-effectiveness analysis Treatment assignment (within CEA)
No (N=113) Yes (N=189) P UC (N=99) Intervention (N=90) P
Age, mean (SD), y 58.8 (10.1) 67.0 (10.4) .74 67.1 (11.5) 66.9 (9.0) .88
Male 54% 61% .21 59% 64% .41
Caucasian 88% 93% .15 93% 92% .85
NHigh School education 57% 54% .61 49% 60% .15
Married 68% 68% .94 67% 69% .74
Working, full, part-time 48% 70% b .0001 75% 66% .17
SF-36v2 MCS, mean (SD) 42.8 (11.5) 43.1 (11.5) .86 42.5 (11.6) 43.7 (11.4) .48
SF-36v2 PCS, mean (SD) 30.3 (6.2) 31.0 (7.5) .40 30.2 (7.5) 31.8 (7.5) .15
PHQ-9 score, mean (SD) 13.6 (3.4) 13.5 (3.4) .91 13.7 (3.7) 13.3 (3.0) .40
Hamilton Rating Scale for Depression, mean (SD) 16.5 (7.3) 16.0 (6.9) .54 15.7 (6.8) 16.4 (6.9) .46
Diabetes 43.4% 42% .79 44% 39% .44
Chronic obstructive pulmonary disease 19% 24% .38 23% 24% .85
Myocardial infarction 44% 48% .57 44% 51% .36
Ejection fraction, mean % (SD) 51 (12.2) 50 (12.6) .73 51 (12.4) 49 (12.7) .41
Medicare only 28% (52) – 31% (31) 23% (21) .50
Private health plan 1 only 36% (68) 34% (34) 38% (34)
Private health plan 2 only 21% (39) 17% (17) 24% (22)
Medicare plus private health plan 16% (30) 17% (17) 15% (13)
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QALYs and DFSs between the groups, respectively. We used the
bootstrapping procedure [35] with 1000 replications of the same
size as our study sample to calculate the ICER with 95% conﬁdence
intervals (CIs). We then generated a cost-effectiveness acceptability
curve to display the probability that the intervention is cost-effective
at or below a given willingness to pay. We created a scatterplot of the
estimated incremental cost versus incremental QALYs and reported
the probability that CC would “dominate” UC (i.e., greater improve-
ment in QALYs at lower cost).
We conducted sensitivity analyses to determine how robust
our estimate of cost-effectiveness was to changes in how costs
were determined. First, we calculated the ICER using raw data on costs
and effectiveness. Second, as the mean costs of our small sample
were heavily inﬂuenced by a single high-cost CC outlier whose total
12-month cost of care was $258,801, we removed this patient from
both our actual and estimated numbers (the next highest cost patient,
also randomized to CC, had 12-month costs of $109,668). Third, we
doubled the estimated cost of our care manager intervention to $920
to account for any costs we may have overlooked in our base case
(e.g., pharmacotherapy costs) and repeated our calculations. We used
SAS 9.2 (SAS Institute Inc., Cary, NC, USA) for all analyses.
2. Results
We obtained completed SF-36 questionnaires on 82%–85% of our
cohort at our 2-, 4- and 8-month assessments points (N=302); on
87% of our cohort who remained eligible for a 12-month assessmentTable 2
Twelve-month total cost comparisons between CC and UC for post-CABG depression
UC
Mean (SD)
Actual, all observations including intervention costs ($460) $17,522 ($21,072
Actual, excluding 1 high-cost outlier in intervention group
Including intervention costs ($460)c
$17,522 ($21,072
Actual, all observations, double intervention costs ($920) $17,522 ($21,072
Estimateda, observations including intervention costs ($460) $18,622 ($6292)
Estimateda, excluding 1 high-cost outlier in the intervention groupc
including intervention costs ($460)
$18,622 ($6292)
Estimateda, all observations, double intervention costs ($920) $18,558 ($6148)
a Estimated costswerebasedonGLMswithgammadistributionand log-link function, including
b Due to the skewed distribution of the data, Wilcoxon nonparametric tests were used to
c The single extreme high-cost outlier in the CC group generated $258,801 in total 12-m(230/269);12-month vital status on 100% (302/302); and complete
12-month insurance claims data on 63% (189/302) (Fig. 1). Just four
subjects (1%) died (three CC and one UC), and we were able to obtain
12-month claims on the two who died in months 9 and 12 after
randomization (both CC). They and the other subjects included in our
cost-effectiveness analyses were more likely to be working at baseline
than the 113 depressed subjects for whom we lacked complete data
(70% vs. 48%; Pb .001), but were otherwise similar on their socio-
demographic and clinical criteria (Table 1). As with our full trial
cohort (N=302) [12], the 189 depressed subjects included in our
cost-effectiveness analyses were balanced by randomization status
(Table 1), and CC patents reported greater improvements on the SF-36
and HRS-D at various follow-up times and more QALYs than UC patients
(0.70 QALYs vs. 0.65 QALYs, P=.004; eTable 1). However, these
differenceswere not uniformly statistically signiﬁcant as described earlier
[12] perhaps due to the smaller sample size.
Table 2 displays the total 12-month costs by randomization status.
Using actual claims data and including the $460 estimated cost of our
intervention, CC patients had a nonsigniﬁcantly $779 higher total
median per capita medical costs than UC patients at 12 months
following randomization ($8359 vs. $7580; P=.60), and neither
excluding the one high-cost outlier from our intervention group
($258,801) nor categorizing total costs into outpatient and inpatient
costs (eTable 2) affected these results. Estimating costs using the GLM
procedure, CC patients had a $2068 lower but still nonstatistically
signiﬁcant difference in median 12-month costs than UC ($16,126 vs.
$18,194; P=.30) that was robust to either excluding the one high-cost
outlier or doubling the estimated per capita cost of our intervention.CC Cost difference, UC−CC
Median Mean (SD) Median Mean Median
Pb
) $7580 $19,279 ($31,369) $8359 −$1757 $779 .60
) $7580 $16,552 ($18,050) $8292 $971 −$712 .69
) $7580 $19,739 ($31,369) $8819 −$2217 −$1239 .34
$18,194 $18,173 ($8316) $16,126 $449 $2068 .30
$18,194 $17,986 ($8174) $15,931 $636 $2263 .24
$18,159 $18,660 ($8332) $16,652 −$102 $1507 .30
gender, age, race, treatmentgroupand interaction termbetweengender and treatmentgroup.
test the differences between the medians of the groups.
onth costs.
Table 3
Incremental mean cost per QALY and per DFD
Incremental cost per QALY, $a (95% CI) Incremental cost per DFD, $a (95% CI)
Actual, all observations 54,605 (44,593 to 64,617) −4 (−391 to 384)
Actual, excluding 1 high-cost outlier in the CC groupb −21,591 (−26,064 to −17,118) −59 (−142 to 25)
Actual, all observations, intervention cost doubled to $920 65,943 (55,234 to 76,653) 44 (−320 to 409)
Estimatedc, all observations −9889 (−11,940 to −7838) −48 (−64 to −31)
Estimatedc, excluding 1 high-cost outlier in the CC groupb −14,539 (−16,125 to −12,952) −49 (−54 to −44)
Estimatedc, all observations, intervention cost doubled to $920 3743 (−163 to 7649) −13 (−26 to −1)
a Costs were estimated using GLMmodel that included treatment group, age, gender, race and interaction term between treatment and gender. Assume $460mean per capita cost
for intervention unless otherwise noted.
b The single extreme high-cost outlier in the CC group generated $258,801 in total 12-month costs.
c QALYs and DFDs were estimated using a mixed model that included treatment, time point, age, gender, and race, and two- and three-way interaction terms between treatment,
time point and gender and bootstrapped to calculate the ICER with 95% CIs.
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and DFD produced by CC. In our estimated models, CC “strongly
dominated” UC (ICER=−$9889; 95% CI: −$11,940 to −$7838), and
removing the extreme cost outlier from our analyses resulted in even
greater dominance (−$14,539;−$16,125 to−$12,952). CC remained
cost-effective even when taking the most conservative approach
using actual costs and including all observations ($54,605; $44,593
to $64,617) and dominated UC again when we removed the single
high-cost outlier (−$21,591; −$26,064 to −$17,118). Furthermore,
the estimated base case model demonstrated a cost savings of −$48
per DFD (−$64 to −$31) that remained signiﬁcant even after we
doubled the estimated cost of our intervention (−$13;−$26 to−$1).
Fig. 2 illustrates the estimated cost-effectiveness acceptability
curves for our three scenarios. We see the base case analysis of the BtB
intervention as having a 98% probability of being cost-effective at a
societal willingness to pay up to $50,000 per additional QALY and a
90% probability of being cost-effective at the $20,000 “high-value
care” threshold recommended for rapid dissemination [36].
Moreover, these probabilities were little affected by excluding the
high-cost outlier, doubling the cost of our intervention (96% and 79%
probability cost-effective at the $20,000 threshold, respectively), or
removing the three-way treatment, time point and gender interaction
term. A cost-effectiveness scatterplot involving 1000 bootstrapped
replication of the BtB trial population found CC as likely to be bothmore
effective and cost less than UC as 68% of replications fell in the
“dominant” right lower quadrant (Fig. 3). Moreover, removing the
single high-cost outlier or doubling the cost of the BtB intervention had
only modest affects on the probability that CC would continue to
“dominate” UC (73% and 47%, respectively; not shown).0
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Fig. 2. Cost-effectiveness acceptability curves of CC versus UC for post-CABG depression.3. Discussion
To the best of our knowledge, this is the ﬁrst economic evaluation
of a CC strategy for treating depression following an acute cardiac
event. Just one other group has reported the cost-effectiveness of a
systematic depression treatment program for patients with coronary
disease [23,24]. They employed mental health professionals who
delivered their interventions either face-to-face [13,23] or in combina-
tion with telephone and video contacts among patients with stable
cardiac diseasewhowere recruited fromoutpatient settings [13,24] and
also reported nonsigniﬁcant estimated total cost reductions favoring
their intervention (e.g., −$325 lower mean costs; 95% CI: −$2639 to
$1989 [24]). Yet while they used estimated rather than actual Medicare
claims data, our ﬁndings are consistent as they also reported that their
programwas likely to be cost-effective (98% probability cost-effective at
a willingness to pay of $30,000 per additional QALY [23]).
This is also the ﬁrst report to describe a statistically signiﬁcant
negative ICER for a CC strategy for treating depression in any patient
population. Gilbody et al.'s [18] 2006 systematic review of 11
randomized economic evaluations of CC interventions delivered in
primary care to younger and mixed-age populations concluded that
these programs improve outcomes, but at a greater cost than UC.
Although they were unable to calculate a summary measure of
incremental cost per QALY, they did summarize the cost per added
DFD at $24 (−$105 to $148) versus the−$48 cost per added DFD we
report (−$64 to −$31; Table 3).
Not included in Gilbody et al.'s review are the cost-effectiveness
analyses from the Improving Mood Promoting Access to Collaborative
Treatment (IMPACT) [19] and TEAMcare Trials [20]. IMAPCT involved
1801 primary care patients aged 60 and older who were randomized
to either a CC intervention provided by a nurse- or psychologist-care
manager or to their PCPs' UC [37]. At 2-year follow-up, intervention
patients had $691 higher total health care costs ($16,175 vs. $15,484)
and 107 more DFDs which translated to an incremental outpatient
cost per QALY of $2519 (−$4517 to $9554) and $2.76 cost per
additional DFD (−$4.95 to $10.47) [19]. TEAMcare randomized 214
depressed adults with poorly controlled diabetes or coronary
heart disease to either 12 months of a nurse-led “blended” CC
strategy for treating depression and diabetes, or to their doctors' UC
[38]. At 2-year follow-up, their intervention produced favorable but
nonsigniﬁcant cost savings versus UC ($594 lower estimated mean
outpatient costs; ICER:−$1773 estimated outpatient costs per added
QALY (−$2878 to $2878)), at an outpatient cost of −$5.26 per DFD
(−$29,76 to $19.17) [20]. However, as in IMPACT, most cost savings
occurred between the ﬁrst and second years of follow-up, stressing
the continued need for adequately powered and longer-term trials
that examine the effects of depression treatment on costs. Given the
increasingly negative (favorable) cost per DFD found when CC is
applied to more medically ill populations, we conclude that the cost-
effectiveness of CC programs is likely to be greater when applied to
patients who tend to utilize high levels of medical services (e.g., the
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Fig. 3. Estimated cost-effectiveness plane of incremental cost versus incremental QALYs based on 1000 bootstrapped replication of the Bypassing the Blues trial population and all
observations. Notably, 68% of replications are in the “dominant” quadrant.
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groups of primary care patients whose baseline ambulatory care-
sensitive use of nonmental health specialists, emergency rooms, and
hospitalizations, and medical spending on pharmaceuticals and other
services are relatively lower.
Conﬁdence in our ﬁndings is further strengthened as we used the
actual numbers of nurse contacts [12], incorporated physician supervi-
sion time and other expenses to calculate the $460 cost to provideour 8-
month intervention, and bootstrapped our estimate of the ICER rather
than use a raw number coming from a single sample. Thus, it is of great
interest that the estimated ICER of our intervention was negative and
remained so even after we doubled the cost of our intervention to $920
and well above the $535 [23] to $687 [24] estimated 6-month
costs to provide mental health care to depressed cardiac patients, the
$515 1-year costs to deliver CC for depression to predominantly low-
income Hispanics [39], or the $591 1-year cost to provide the IMPACT
version of CC to depressed older primary care patients [19].
Despite our encouragingﬁndings, uptake of the BtB intervention and
others similar to it will depend in large part on whether its key
components are adequately reimbursed by payers— either as individual
services, bundled payments or incentives for achieving predeﬁned goals
(e.g., reduced use of emergency rooms and hospitalizations)— to allow
payment for depression screening, telephone outreach, nurse care
management and coordination, and psychiatrist supervision [40].
Because payers make coverage and reimbursement decisions based on
information about an intervention's value at a population level,
implementation of CC is thus reliant on high-quality evidence
demonstrating that it is both effective and cost-effective. Although
there is no ofﬁcial US standard, medical treatments that have an
incremental cost per QALY of $50,000 or less are considered reasonable
values, and those that cost under $20,000 are often recognized as “high-
value” care recommended for rapid dissemination [36]. Therefore, if we
estimate 400,000 CABG surgeries are performed annually in the United
States [41] and assume a conservative 20% incident rate of post-CABG
depression [3,12] and a median 12-month savings of $2068 per treated
patient (Table 2), then telephone-delivered CC for post-CABG depres-
sion has the potential to save $165 million in the ﬁrst year following
surgery as well as generate signiﬁcant improvements in HRQoL and
speed recovery [12,26].The results of our analyses should be interpreted in light of
several limitations. First, BtB was powered to detect differences in
HRQoL between study arms [12] rather than economic outcomes. Still,
analyses of our trial data provide an unbiased view of the comparative
outcome of clinical strategies [42]. Second, although we noted no
differences in baseline characteristics other than employment status,
we were only able to obtain complete 12-month claims on 62% of trial
participants and lacked complete information on prescription drug
spending. Third, because of our relatively small sample size and
nonsigniﬁcant overall cost differences, we choose not to categorize
cost data into multiple cost categories. However, we did split total
medical costs into its inpatient and outpatient cost components and
found no signiﬁcant differences by treatment assignment (eTable 2).
Finally, while our ﬁndings are consistent with other trials suggesting
that CC is cost-effective, BtB was a single trial conducted in one region
of the country with relatively short follow-up, and thus, our ﬁndings
should be conﬁrmed in a larger multisite trial with longer follow-up.
In summary, centralized, nurse-provided and telephone-delivered
CC for post-CABG depression is a quality-improving, cost-effective and
high-value treatment that meets generally accepted criteria for rapid
dissemination. Moreover, our ﬁndings support the AHA's Science
Advisory advocating the increased awareness, and routine screening
and treatment of all patients with cardiovascular disease for
depression and have important implications for health policy makers
and providers considering integrated delivery of mental health and
medical services.
Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.genhosppsych.2014.05.012.
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